Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new offering enables biotechnology and ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

ProBio's proprietary platform utilizes an optimized single-domain antibody (sdAb) targeting CD3, overcoming these challenges by enablingthe development of highly adaptable bispecific and multi ...

CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.39%, which has investors questioning if this is right time to ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...

This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific ...